Banque Transatlantique’s iShares Biotechnology ETF IBB Stock Holding History

Banque Transatlantique’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$656K	Buy	+3,447	New	+$592K	0.01%	203

Other funds holding IBB

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

AFG

Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return

Banque Transatlantique's IBB Position: Q2 2026 in Review

Banque Transatlantique opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 3,447 shares worth $656K. The stake represents 0.01% of the portfolio and ranks #203 among its holdings.

601 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Banque Transatlantique held 3,447 shares of iShares Biotechnology ETF worth $656K as of Q2 2026.
iShares Biotechnology ETF was a new Banque Transatlantique position in Q2 2026.
iShares Biotechnology ETF made up 0.01% of Banque Transatlantique's portfolio in Q2 2026, its #203 holding.
601 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Banque Transatlantique's 13F filing for Q2 2026, filed 30 Jul 2026.